← back to search

Dong Yang

University of Connecticut · US
Area of research
Immunology · Oncology
Research interest
Research interests include Immune cells in cancer, Cancer Immunotherapy and Biomarkers, Ovarian cancer diagnosis and treatment, and Cancer-related molecular mechanisms research.
h-index
20
citations
1,907
works
72
NIH funding
primary concept
email

Recent publications

2774P DAREON®-9: A phase Ib open-label dose escalation and dose confirmation study of obrixtamig (BI 764532) plus topotecan in patients (pts) with advanced small-cell lung cancer (SCLC): Updated results
Annals of Oncology 2025cited by 1position: middledoi
TRPML1 triggers ferroptosis defense and is a potential therapeutic target in AKT-hyperactivated cancer
Science Translational Medicine 2024cited by 52position: middledoi
Tubastatin A potently inhibits GPX4 activity to potentiate cancer radiotherapy through boosting ferroptosis
Redox Biology 2023cited by 97position: middledoi
Analysis of risk factors of precocious puberty in children
BMC Pediatrics 2023cited by 21position: middledoi
The potential health effects associated with electronic-cigarette
Environmental Research 2023cited by 18position: middledoi
Correction: Analysis of risk factors of precocious puberty in children
BMC Pediatrics 2023cited by 3position: middledoi
FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer
Nature Communications 2021cited by 180position: middledoi
Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis
Signal Transduction and Targeted Therapy 2021cited by 136position: middledoi
Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma
Molecular Cancer 2020cited by 73position: middledoi
1434P A prospective, multicenter, non-randomized, controlled trial of apatinib plus perioperative chemotherapy with FLOT protocol and surgery for the treatment of stage III gastric cancer
Annals of Oncology 2020cited by 7position: middledoi
Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
Clinical Cancer Research 2019cited by 121position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Xiao‐Feng Zhu · Shandong University of Traditional Chinese Medicine6 papers (2019–2024)Rong Deng · Shanghai Jiao Tong University6 papers (2019–2024)Gong-Kan Feng · Sun Yat-sen University6 papers (2019–2024)Zhi‐Ling Li · Ningxia Normal University5 papers (2019–2024)Hai‐Liang Zhang · Sun Yat-sen University4 papers (2019–2024)Bingxin Hu · Anhui University4 papers (2020–2024)Yuhong Chen · Chinese Academy of Medical Sciences & Peking Union Medical College4 papers (2020–2023)Yun Huang · Sun Yat-sen University4 papers (2019–2021)Xiao-Dan Peng · Peking University Shenzhen Hospital4 papers (2019–2021)Li-Huan Zhou · Central South University4 papers (2019–2021)Tian Du · Sun Yat-sen University3 papers (2021–2024)Yu-Hong Chen · Sun Yat-sen University2 papers (2019–2024)Limin Chu · First Affiliated Hospital of Hebei Medical University2 papers (2023–2023)Yan Wang · Kunming University of Science and Technology2 papers (2020–2021)Xuan Li · University of Science and Technology of China2 papers (2019–2021)Zhifang Li · Fujian Normal University2 papers (2023–2023)Kaiming Zhang · Shanxi Medical University2 papers (2021–2021)Jun Tang · Hubei University of Medicine2 papers (2020–2021)Lichao Li · Tianjin University of Technology2 papers (2023–2024)Lili Dai · Ningbo University2 papers (2023–2023)